Bay City Capital, a venture capital firm focused on early-stage to growth equity investments in the life sciences, has appointed David Beier, JD as managing director.
Beier (pictured) served as a senior officer for nearly a decade in each of the two largest biotechnology firms, Genentech and Amgen. Most recently, he served as senior vice president of global government affairs at Amgen, responsible for global government affairs, as well as corporate communications, and philanthropy.
“Today’s rapidly evolving healthcare industry provides tremendous opportunity for investment both in the US and globally. David brings an extensive government affairs and public policy background, providing unique insights to our investment team,” says Fred Craves, founder and managing director of Bay City Capital. “David will play an integral role in moving the firm forward through the next phase of global healthcare investing.”
During his Amgen tenure, Beier helped create and supervised the firm’s coverage, reimbursement, access, pricing, and healthcare economics activities globally. Earlier in his career, Beier was chief domestic policy advisor to Vice President Al Gore during the Clinton Administration. Beier has been a partner in a large international law firm as well as counsel to the US House of Representatives Committee on the Judiciary. He is admitted to practice law in New York and the District of Columbia.
“Bay City Capital has a well deserved reputation of delivering value for its investors and its portfolio companies through a vibrant platform of scientific and business acumen. Those characteristics are what attracted me to the firm,” says Beier.
